E. Kutarska

1 ta ish

Lublin Oncology Center

1. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

   M. M. Heiss, P. Murawa, P. Koralewski +17

   Maqola20102 iqtibos

   ABIABI:AkademIndex/2026.other.913710